Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report 2025
신경근 질환용 핵산 및 유전자 치료 시장 규모는 향후 몇 년 동안 큰 폭의 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 유전 질환의 유병률 증가, 연구 개발에 대한 투자 증가, 정밀 의학에 대한 수요 증가, 유전자 치료 제품 승인 급증, 만성 질환의 발병률 증가에 의해 주도될 수 있습니다. 이 기간의 주요 트렌드에는 환자 치료의 발전, 고성능 크로마토그래피, 혁신적인 치료 솔루션, 유전자 편집 기술의 발전, 첨단 핵산 추출 기술의 가용성 등이 포함됩니다.
유전 질환의 유병률 증가는 신경근육 질환 시장에서 핵산 및 유전자 치료법의 성장을 견인할 것으로 예상됩니다. 유전 질환은 유전되거나 돌연변이로 인한 개인의 DNA 이상에서 발생합니다. 이러한 장애의 증가는 유전적 돌연변이, 환경적 영향, 라이프스타일 변화, 진단 기술의 발전과 같은 요인에 기인합니다. 핵산 및 유전자 치료는 결함이 있는 유전자를 교정하거나 대체하여 정상적인 기능을 회복함으로써 유전성 신경근육 질환을 해결하는 데 중요한 역할을 합니다. 예를 들어, 2024년 5월 미국의 비영리 단체인 Cure SMA에 따르면 현재 미국에서 약 9,000-9,500명이 척수성 근위축증(SMA)을 앓고 있으며, 이 중 2형 SMA가 37%를 차지합니다. SMA의 추정 발병률은 출생아 15,000명 중 약 1명입니다. 결과적으로 유전 질환의 유병률이 증가함에 따라 신경근육 질환 시장에서 핵산 및 유전자 치료제에 대한 수요가 증가하고 있습니다.
시장을 선도하는 기업들은 정밀한 유전자 교정 또는 교체를 통해 유전적 신경근육 질환의 근본 원인을 직접 겨냥하는 유전자 치료 솔루션을 발전시키고 있습니다. 유전자 치료는 결함이 있는 유전자를 해결하기 위해 환자의 세포 내 유전 물질을 수정하거나 복구하는 것을 포함합니다. 예를 들어, 2023년 6월 미국 생명공학 회사인 Sarepta Therapeutics는 4-5세 외래 소아 환자를 대상으로 한 최초의 듀센 근이영양증(DMD) 유전자 치료제인 Elevidys에 대한 FDA 승인을 받았습니다. 엘리비디스는 1회 정맥 주입으로 투여할 수 있어 지속적인 주입 기반 치료에 대한 간소화된 대안을 제공합니다. 이 치료법은 근육 기능에 중요한 마이크로 디스트로핀으로 알려진 단축된 형태의 디스트로핀을 코딩하는 유전자를 전달합니다. 근육 세포가 기능성 디스트로핀 단백질을 생산할 수 있도록 함으로써 Elevidys는 질병 진행을 늦추거나 잠재적으로 역전시키는 것을 목표로 합니다.
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 신경근 질환용 핵산 및 유전자 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 성장률 분석
- 세계의 신경근 질환에서의 핵산 및 유전자 치료 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 신경근 질환에서의 핵산 및 유전자 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 신경근 질환용 핵산 및 유전자 치료 총 시장 규모(TAM)
제6장 시장 세분화
- 세계의 신경근 질환용 핵산 및 유전자 치료 시장 장애에 의해 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 운동 뉴런 질환
- 신경 장애
- 신경근 접합부 질환
- 근이영양증을 포함한 근병증
- 세계의 신경근 질환에서의 핵산 및 유전자 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 아데노 관련 바이러스 유전자 치료
- 출생 후 유전자 치료
- 척수근 위축증
- 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 전문 클리닉
- 외래수술센터(ASC)
- 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 운동 뉴런 질환 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 근위축성 측삭 경화증(ALS)
- 척수성 근위축증(SMA)
- 원발성 측삭 경화증(PLS)
- 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 신경 장애 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 샤르코-마리-투스병(CMT)
- 유전성 감각 자율 신경 장애(HSAN)
- 말초 신경 장애
- 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 신경근 접합부 질환 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 중증 근무력증
- 램버트-이튼 중증 근무력증 증후군(LEMS)
제7장 지역별 및 국가별 분석
- 세계의 신경근 질환용 핵산 및 유전자 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 신경근 질환에서의 핵산 및 유전자 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 신경근 질환에서 핵산 및 유전자 치료 시장 : 경쟁 구도
- 신경근 질환에서 핵산 및 유전자 치료 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- F. Hoffmann-La Roche Ltd. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Eli Lilly and Company
- Astellas Pharma Inc
- Biogen Inc
- Vertex Pharmaceuticals Inc
- BioMarin Pharmaceuticals Inc
- Nippon Shinyaku Co Ltd
- Sarepta Therapeutics Inc
- Ionis Pharmaceuticals, Inc.
- Ultragenyx Pharmaceutical Inc
- Amicus Therapeutics Inc
- Arrowhead Pharmaceuticals Inc
- Regenxbio Inc
- UniQure NV
- Genethon SA
- Axovant Gene Therapies, Inc
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 신경근 질환용 핵산 및 유전자 치료 시장(2029년) : 새로운 기회를 제공하는 국가
- 신경근 질환에서 핵산 및 유전자 치료 시장(2029년) : 새로운 기회를 제공하는 부문
- 신경근 질환에서의 핵산 및 유전자 치료 시장(2029년) : 성장 전략
제36장 부록
HBR
Nucleic acid and gene therapies for neuromuscular disorders are innovative treatments designed to correct or compensate for genetic mutations that cause these conditions. Neuromuscular disorders (NMDs) affect the muscles and nerves, often due to inherited mutations. These therapies utilize nucleic acids or genetic material to repair, replace, or modulate gene expression, addressing the underlying cause of the disorder.
The primary disorders targeted by these therapies include motor neuron diseases, neuropathies, neuromuscular junction disorders, and myopathies such as muscular dystrophies. Motor neuron diseases are a group of progressive neurological conditions that impact motor neurons, leading to muscle weakness, atrophy, and loss of voluntary movement control. Treatment approaches include adeno-associated virus (AAV) gene therapy, postnatal gene therapy, and therapies for spinal muscular atrophy. These therapies are applied in various healthcare settings, including hospitals, specialty clinics, and ambulatory surgery centers.
The nucleic acid and gene therapies in neuromuscular disorders market research report is one of a series of new reports from The Business Research Company that provides nucleic acid and gene therapies in neuromuscular disorders market statistics, including nucleic acid and gene therapies in neuromuscular disorders industry global market size, regional shares, competitors with a nucleic acid and gene therapies in neuromuscular disorders market share, detailed nucleic acid and gene therapies in neuromuscular disorders market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid and gene therapies in neuromuscular disorders industry. This nucleic acid and gene therapies in neuromuscular disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The nucleic acid and gene therapies in neuromuscular disorders market size has grown strongly in recent years. It will grow from $6.84 billion in 2024 to $7.52 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth during the historic period can be attributed to an increase in regulatory approvals, rising demand for nucleic acid therapeutics, a growing need for more precise and effective treatments, heightened demand for gene therapies, and an increasing number of gene therapy-based discoveries.
The nucleic acid and gene therapies in neuromuscular disorders market size is expected to see strong growth in the next few years. It will grow to $10.87 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth during the forecast period can be driven by the rising prevalence of genetic disorders, increased investments in research and development, growing demand for precision medicine, a surge in gene therapy product approvals, and a higher incidence of chronic disorders. Key trends in this period include advancements in patient care, high-performance chromatography, innovative treatment solutions, progress in gene editing technologies, and the availability of advanced nucleic acid extraction technology.
The increasing prevalence of genetic disorders is expected to drive the growth of the nucleic acid and gene therapies in the neuromuscular disorders market. Genetic disorders arise from abnormalities in an individual's DNA, either inherited or resulting from mutations. The rise in these disorders is attributed to factors such as genetic mutations, environmental influences, lifestyle changes, and advancements in diagnostic technologies. Nucleic acid and gene therapies play a crucial role in addressing genetic neuromuscular disorders by correcting or replacing defective genes to restore normal function. For example, in May 2024, according to Cure SMA, a US-based non-profit organization, approximately 9,000 to 9,500 individuals in the United States are currently living with Spinal Muscular Atrophy (SMA), with Type 2 SMA accounting for 37% of cases. The estimated incidence rate of SMA is approximately 1 in 15,000 births. As a result, the growing prevalence of genetic disorders is fueling the demand for nucleic acid and gene therapies in the neuromuscular disorders market.
Leading companies in the market are advancing gene therapy solutions to directly target the root causes of genetic neuromuscular conditions through precise gene correction or replacement. Gene therapy involves modifying or repairing genetic material within a patient's cells to address defective genes. For instance, in June 2023, Sarepta Therapeutics Inc., a US-based biotechnology company, received FDA approval for Elevidys, the first gene therapy for Duchenne Muscular Dystrophy (DMD) in ambulatory pediatric patients aged 4 to 5 years. Elevidys is administered as a single intravenous infusion, offering a simplified alternative to ongoing infusion-based therapies. This therapy delivers a gene encoding a shortened form of dystrophin, known as micro-dystrophin, which is crucial for muscle function. By enabling muscle cells to produce a functional dystrophin protein, Elevidys aims to slow or potentially reverse disease progression.
In November 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired Kate Therapeutics Inc. for $1.1 billion. This acquisition aims to strengthen Novartis' gene therapy portfolio for inherited neuromuscular diseases. By integrating Kate Therapeutics' AAV-based gene therapy platform DELIVER and its preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1, Novartis is expanding its capabilities in developing targeted therapies for genetic muscle and heart diseases. Kate Therapeutics Inc. is a US-based biotechnology company specializing in adeno-associated virus (AAV)-based gene therapies for genetically defined neuromuscular conditions.
Major players in the nucleic acid and gene therapies in neuromuscular disorders market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A, Novartis AG, Eli Lilly and Company, Astellas Pharma Inc, Biogen Inc, Vertex Pharmaceuticals Inc, BioMarin Pharmaceuticals Inc, Nippon Shinyaku Co Ltd, Sarepta Therapeutics Inc, Ionis Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc, Amicus Therapeutics Inc, Arrowhead Pharmaceuticals Inc, Regenxbio Inc, UniQure N.V., Genethon S.A, Axovant Gene Therapies Inc.
North America was the largest region in the nucleic acid and gene therapies in neuromuscular disorders market in 2024. The regions covered in nucleic acid and gene therapies in neuromuscular disorders report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nucleic acid and gene therapies in neuromuscular disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The nucleic acid and gene therapies in neuromuscular disorders market consist of revenue earned by entities by providing services such as genetic diagnostics, personalized therapeutics, and gene delivery. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid and gene therapies in neuromuscular disorders market also include sales of oligonucleotides, gene therapy vectors, and diagnostic kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nucleic Acid And Gene Therapies In Neuromuscular Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nucleic acid and gene therapies in neuromuscular disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for nucleic acid and gene therapies in neuromuscular disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nucleic acid and gene therapies in neuromuscular disorders market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Disorder: Motor Neuron Diseases; Neuropathies; Neuromuscular Junction Disorders; Myopathies Including Muscular Dystrophies
- 2) By Therapy: Adeno-Associated Viruses Gene Therapy; Postnatal Gene Therapy; Spinal Muscular Atrophy
- 3) By Application: Hospitals; Specialty Clinics; Ambulatory Surgery Centers
- Subsegments:
- 1) By Motor Neuron Diseases: Amyotrophic Lateral Sclerosis (ALS); Spinal Muscular Atrophy (SMA); Primary Lateral Sclerosis (PLS)
- 2) By Neuropathies: Charcot-Marie-Tooth Disease (CMT); Hereditary Sensory and Autonomic Neuropathy (HSAN); Peripheral Neuropathies
- 3) By Neuromuscular Junction Disorders: Myasthenia Gravis; Lambert-Eaton Myasthenic Syndrome (LEMS)
- 4) By Myopathies Including Muscular Dystrophies: Duchenne Muscular Dystrophy (DMD); Becker Muscular Dystrophy (BMD); Limb-Girdle Muscular Dystrophy (LGMD); Facioscapulohumeral Muscular Dystrophy (FSHD)
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bayer AG; Sanofi S.A; Novartis AG
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Characteristics
3. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Trends And Strategies
4. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Growth Analysis And Strategic Analysis Framework
- 5.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Growth Rate Analysis
- 5.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Total Addressable Market (TAM)
6. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Segmentation
- 6.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Motor Neuron Diseases
- Neuropathies
- Neuromuscular Junction Disorders
- Myopathies Including Muscular Dystrophies
- 6.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Adeno-Associated Viruses Gene Therapy
- Postnatal Gene Therapy
- Spinal Muscular Atrophy
- 6.3. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Specialty Clinics
- Ambulatory Surgery Centers
- 6.4. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Motor Neuron Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Amyotrophic Lateral Sclerosis (ALS)
- Spinal Muscular Atrophy (SMA)
- Primary Lateral Sclerosis (PLS)
- 6.5. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuropathies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Charcot-Marie-Tooth Disease (CMT)
- Hereditary Sensory and Autonomic Neuropathy (HSAN)
- Peripheral Neuropathies
- 6.6. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Sub-Segmentation Of Neuromuscular Junction Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Myasthenia Gravis
- Lambert-Eaton Myasthenic Syndrome (LEMS)
7. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Regional And Country Analysis
- 7.1. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 8.1. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 9.1. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 9.2. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 10.1. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 11.1. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 11.2. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 12.1. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 13.1. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 14.1. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 14.2. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 15.1. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 15.2. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 16.1. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 17.1. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 18.1. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 19.1. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 20.1. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 21.1. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 21.2. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 22.1. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 23.1. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 23.2. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 24.1. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 24.2. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 25.1. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 25.2. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 26.1. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 26.2. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 27.1. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 28.1. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 28.2. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
- 29.1. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Overview
- 29.2. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape And Company Profiles
- 30.1. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Landscape
- 30.2. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Other Major And Innovative Companies
- 31.1. Eli Lilly and Company
- 31.2. Astellas Pharma Inc
- 31.3. Biogen Inc
- 31.4. Vertex Pharmaceuticals Inc
- 31.5. BioMarin Pharmaceuticals Inc
- 31.6. Nippon Shinyaku Co Ltd
- 31.7. Sarepta Therapeutics Inc
- 31.8. Ionis Pharmaceuticals, Inc.
- 31.9. Ultragenyx Pharmaceutical Inc
- 31.10. Amicus Therapeutics Inc
- 31.11. Arrowhead Pharmaceuticals Inc
- 31.12. Regenxbio Inc
- 31.13. UniQure N.V.
- 31.14. Genethon S.A
- 31.15. Axovant Gene Therapies, Inc
32. Global Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
34. Recent Developments In The Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market
35. Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market High Potential Countries, Segments and Strategies
- 35.1 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Nucleic Acid And Gene Therapies In Neuromuscular Disorders Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
